Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AE58054 augmentation therapy to risperidone in patients with schizophrenia
2008-001441-26Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Lu AE58054 + risperidone with Placebo + risperidone (2 arms). Primary endpoint: Change from baseline in PANSS total score. Started Sep 2008; status: completed.
02
Drugs
Idalopirdine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2008-001441-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001441-26.